Key statistics
As of last trade KALA BIO Inc (0JQ2:LSE) traded at 0.376, 8.42% above its 52-week low of 0.3468, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 0.376 |
| Low | 0.376 |
| Bid | -- |
| Offer | -- |
| Previous close | 0.385 |
| Average volume | 21.23k |
|---|---|
| Shares outstanding | 911.33m |
| Free float | 911.27m |
| P/E (TTM) | -- |
| Market cap | 346.31m USD |
| EPS (TTM) | -5.94 USD |
Data delayed at least 20 minutes, as of Mar 02 2026 15:28 GMT.
More ▼
Announcements
- KALA BIO Settles Approximately $10.6 million of Debt
- KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
- KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
- KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
- KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
- KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
- KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
More ▼
